Warner Pharmaceuticals (688799.SH) subsidiary esomeprazole magnesium API application approved

Zhitongcaijing · 1d ago

Zhitong Finance App News, Warner Pharmaceuticals (688799.SH) issued an announcement. Recently, Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Chemical Ingredient Marketing Application Approval Notice” for esomeprazole magnesium issued by the State Drug Administration and publicized it on the “Original Auxiliary Package Registration Information” platform of the China Drug Administration (CDE).

According to reports, esomeprazole magnesium is the raw material for pharmaceutical products such as esomeprazole magnesium enteric capsules. Esomeprazole magnesium enteric capsules are mainly used for gastroesophageal reflux disease (GERD); to eradicate Helicobacter pylori in combination with appropriate antimicrobial therapy; and patients requiring continuous NSAID treatment. According to the project cooperation contract signed between the company and Guangdong Bidi Pharmaceutical Co., Ltd., etc., the ownership of the esomeprazole magnesium API approved for marketing this time belongs to Guangdong Bidi Pharmaceutical Co., Ltd., and the company does not enjoy its ownership rights; it is only an API manufacturer.